The table details the average cycle threshold (Ct) for each tissue and gene analyzed. Ct values in italics underline type corresponded to genes considered not expressed for a given group of samples. This category includes all genes with Ct values over 35 (upper limit of detection) and those with undeterminable Ct values. GDNF was considered unexpressed in all tissues because the PCR system flagged all its measurements in spite that the CT values were just below 35. VLVT corresponds to velvet, MSC to mesenchyme, PED to pedicle skin, and FR to frontal skin.

qRT-PCR is a generally acknowledged method for gene expression analysis due to its precision and reproducibility. However, it is well known that the accuracy of qRT-PCR data varies greatly depending on the experimental design and data analysis. Recently, a set of guidelines has been proposed that aims to improve the reliability of qRT-PCR. However, there are additional factors that have not been taken into consideration in these guidelines that can seriously affect the data obtained using this method. In this study, we report the influence that object morphology can have on qRT-PCR data. We have used a number of Arabidopsis thaliana mutants with altered floral morphology as models for this study. These mutants have been well characterised (including in terms of gene expression levels and patterns) by other techniques. This allows us to compare the results from the qRT-PCR with the results inferred from other methods. We demonstrate that the comparison of gene expression levels in objects that differ greatly in their morphology can lead to erroneous results.

PCR & Real-time PCR Molecular Diagnostics Market Outlook

According to our latest research, the global PCR & Real-time PCR Molecular Diagnostics market size reached USD 7.4 billion in 2024, showcasing robust momentum driven by technological advancements and heightened demand for molecular diagnostics. The market is experiencing a healthy expansion, with a CAGR of 7.2% projected from 2025 to 2033. By the end of 2033, the market is forecasted to attain a value of USD 13.8 billion. Key growth factors include the rising prevalence of infectious diseases, increasing adoption of PCR-based diagnostic techniques, and significant investments in healthcare infrastructure worldwide.

The primary growth driver for the PCR & Real-time PCR Molecular Diagnostics market is the escalating need for accurate, rapid, and sensitive diagnostic solutions across a spectrum of diseases. The global healthcare sector has seen a paradigm shift towards early disease detection and personalized medicine, which has significantly increased the adoption of PCR and real-time PCR technologies. The COVID-19 pandemic further amplified the importance of these technologies, as they became the gold standard for detecting viral infections. This trend is expected to continue, as healthcare providers and governments worldwide invest in molecular diagnostic capabilities to combat both existing and emerging infectious diseases. Additionally, the growing awareness among clinicians and patients regarding the benefits of molecular diagnostics is fostering market expansion.

Another critical factor fueling market growth is the continuous technological advancements in PCR instruments, reagents, and software. The development of next-generation PCR platforms that offer higher throughput, automation, and multiplexing capabilities has transformed laboratory workflows, making molecular diagnostics more efficient and cost-effective. Leading manufacturers are focusing on integrating artificial intelligence and cloud-based data analytics into PCR systems, enabling real-time monitoring, remote diagnostics, and improved data management. These innovations not only enhance diagnostic accuracy but also reduce turnaround times, making PCR-based molecular diagnostics indispensable in critical care settings, epidemiological surveillance, and routine clinical practice.

The expansion of healthcare infrastructure and diagnostic laboratories, particularly in developing regions, is another influential growth factor for the PCR & Real-time PCR Molecular Diagnostics market. Governments and private organizations are increasingly investing in healthcare modernization, leading to the establishment of new diagnostic centers and research institutes equipped with advanced molecular diagnostic technologies. This expansion is complemented by favorable regulatory policies, reimbursement frameworks, and public-private partnerships aimed at improving access to high-quality diagnostic services. As a result, the market is witnessing a surge in demand from hospitals, clinics, and academic institutions, further solidifying its growth trajectory.

From a regional perspective, North America continues to dominate the PCR & Real-time PCR Molecular Diagnostics market, accounting for the largest share in 2024. This leadership is attributed to the region's well-established healthcare infrastructure, significant R&D investments, and rapid adoption of advanced diagnostic technologies. Europe follows closely, benefiting from strong government support and a high prevalence of chronic and infectious diseases. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market, propelled by rising healthcare expenditures, expanding patient populations, and increasing awareness about the benefits of molecular diagnostics. Latin America and the Middle East & Africa are also witnessing steady growth, albeit at a relatively slower pace, due to gradual improvements in healthcare access and infrastructure.

Product Type Analysis

The Product

Reagents & Consumables: This segment encompasses a wide array of crucial components, including high-quality primers and probes optimized for various applications, nucleotides, and robust enzymes designed for optimal performance and consistent results. Innovation in this area continuously improves assay sensitivity and specificity.Instruments: The market encompasses a range of instruments, from basic thermal cyclers to sophisticated platforms with advanced features such as real-time fluorescence detection, high-throughput capabilities, and integrated data analysis software. The ongoing development of these instruments is a primary driver of market growth.Software & Services: Sophisticated software packages are essential for data acquisition, analysis, and interpretation. This includes specialized software for gene expression analysis, genotyping, and other applications. Furthermore, comprehensive service offerings, such as installation, training, and technical support, are vital for ensuring optimal instrument performance and data reliability. Recent developments include: February 2022:The COVID-19 PCR tests were expanded by F. Hoffmann-La Roche Ltd. in nations that accepted the C.E. market. It is projected that company expansion will boost its market share., May 2020:The SARS-CoV-2 multiplex real-time PCR test was given emergency use permission (EUA) by the US FDA to Thermo Fisher Scientific, Inc., September 2020:Roche Diagnostics gave the cobas BKV test US FDA 510k approval., May 2020:Abbott Laboratories was approved by the US FDA for a SARS-CoV-2 ass.. Notable trends are: Rising Incidence of Genetic Disorders & Life-Threatening Infectious Diseases will boost the market growth.

The PCR Software and Analysis Tools market is experiencing robust growth, driven by the increasing adoption of PCR technology across various applications, including diagnostics, research, and forensics. The market's expansion is fueled by several key factors: the rising prevalence of infectious diseases necessitating rapid and accurate diagnostics, the growing demand for personalized medicine and pharmacogenomics research leveraging PCR data analysis, and advancements in next-generation sequencing (NGS) technologies that are integrated with PCR workflows. Furthermore, the development of user-friendly software with advanced analytical capabilities, including automation and cloud-based solutions, is simplifying complex data analysis and making PCR technology more accessible to a wider range of users. The market is segmented by software type (e.g., basic analysis, advanced analysis, NGS integration), application (e.g., clinical diagnostics, research, forensics), and end-user (e.g., hospitals, research institutions, pharmaceutical companies). Competition is intense, with major players like Thermo Fisher Scientific, Bio-Rad, and Qiagen dominating the market through their comprehensive product portfolios and established distribution networks. However, smaller, specialized companies are also emerging, focusing on niche applications and innovative analytical solutions. Despite the significant growth, the market faces certain challenges. High initial investment costs for software and hardware, the need for specialized training and expertise, and data security and privacy concerns can hinder broader adoption, particularly in resource-limited settings. Moreover, the regulatory landscape surrounding PCR-based diagnostics and data analysis varies across different regions, which poses challenges for market expansion. The future of the PCR Software and Analysis Tools market is projected to remain positive, with a significant increase in demand driven by continuous technological advancements, rising healthcare spending, and increasing awareness of the importance of rapid and accurate diagnostics. The focus will likely shift towards more sophisticated, integrated software solutions that can seamlessly integrate with other laboratory information management systems (LIMS) and data analysis platforms to facilitate efficient workflows.

The real-time quantitative PCR (qPCR) detecting system market is experiencing robust growth, driven by the increasing prevalence of infectious diseases, rising demand for rapid diagnostics, and the expanding application of qPCR in research and development. The market, estimated at $2.5 billion in 2025, is projected to exhibit a compound annual growth rate (CAGR) of approximately 8% from 2025 to 2033, reaching a value exceeding $4.5 billion by 2033. This growth is fueled by advancements in qPCR technology, including the development of more sensitive and specific assays, higher throughput systems, and user-friendly software. Furthermore, the integration of qPCR with other technologies, such as microfluidics and lab-on-a-chip devices, is expanding its applications in point-of-care diagnostics and personalized medicine. Key players such as Bio-Rad, Danaher, Thermo Fisher Scientific, and Roche are driving innovation and market expansion through strategic partnerships, acquisitions, and the launch of novel qPCR systems. However, the market faces certain restraints, including the high cost of qPCR instruments and reagents, the need for skilled personnel for operation and data analysis, and regulatory hurdles associated with the development and approval of new assays. Nevertheless, the ongoing demand for accurate and rapid diagnostic solutions, coupled with continuous technological advancements, is expected to overcome these challenges and drive sustained market growth. The segmentation of the market by instrument type (e.g., high-throughput, low-throughput), application (e.g., infectious disease diagnostics, gene expression analysis), and end-user (e.g., hospitals, research laboratories) presents opportunities for specialized players to capitalize on specific niche markets. Geographic growth will likely be strongest in emerging economies as healthcare infrastructure and diagnostic capabilities improve.

The global nucleic acid extraction and real-time PCR analysis system market is anticipated to experience exponential growth in the coming years, driven by advancements in molecular diagnostics and increasing demand for rapid and accurate pathogen detection. The rising prevalence of infectious diseases, coupled with the COVID-19 pandemic, has underscored the need for efficient diagnostic tools. Moreover, technological advancements such as automation and miniaturization contribute to the growing adoption of these systems. Market dynamics reveal significant growth potential in various segments. Geographically, North America holds the largest market share, owing to well-established healthcare infrastructure and a high adoption rate of advanced technologies. Asia-Pacific is anticipated to witness significant growth due to increasing healthcare expenditure and government initiatives to improve healthcare access. Key players such as BD, Shengxiang Biotechnology, and Tianlong Technology are investing heavily in research and development to gain a competitive edge. Overall, the market landscape is expected to remain highly competitive, with opportunities for market penetration and expansion in developing regions.

The global RT-qPCR Kits market is experiencing robust growth, driven by the increasing prevalence of infectious diseases, expanding applications in oncology research, and the rising demand for high-throughput screening in pharmaceutical and biotechnology industries. The market, currently estimated at $2.5 billion in 2025, is projected to grow at a compound annual growth rate (CAGR) of 8% from 2025 to 2033. This significant expansion is fueled by technological advancements leading to more sensitive and specific assays, coupled with the increasing adoption of RT-qPCR in various research and diagnostic settings. Key market drivers include the development of novel reagents and instruments that improve workflow efficiency and data analysis, as well as the growing need for rapid and accurate diagnostics in clinical settings. Several trends are shaping the market's trajectory. The increasing demand for personalized medicine is driving the development of customized RT-qPCR assays, catering to specific patient needs and disease subtypes. Furthermore, the integration of advanced data analytics and automation technologies is streamlining workflows and enhancing the overall efficiency of RT-qPCR techniques. However, factors like the high cost of instruments and reagents and stringent regulatory approvals pose challenges to market expansion. The competitive landscape is characterized by the presence of established players such as Thermo Fisher Scientific, QIAGEN, Roche, and Bio-Rad, alongside emerging companies offering innovative solutions. These companies are actively involved in strategic partnerships, acquisitions, and research and development to maintain a competitive edge and cater to the evolving demands of the market.

Multiplex Real Time PCR Market Outlook

The global multiplex real-time PCR market size was valued at approximately USD 1.5 billion in 2023 and is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 8.6% during the forecast period. This robust growth is primarily driven by advancements in molecular biology techniques, increasing incidences of infectious diseases, and the rising demand for precise diagnostic tools.

The multiplex real-time PCR market is experiencing substantial growth due to its extensive application in detecting multiple pathogens in a single reaction, which significantly enhances the efficiency and speed of diagnostic testing. This is particularly critical in the healthcare sector, where rapid and accurate diagnosis is essential for effective treatment. The COVID-19 pandemic further highlighted the importance of such advanced diagnostic tools, propelling the demand for multiplex real-time PCR technologies. Additionally, the integration of PCR with advanced software for data analysis and interpretation is another driving factor, enabling more comprehensive and precise results.

Another significant growth factor is the increasing research activities in the fields of genomics and molecular biology. As scientists endeavor to understand the genetic basis of diseases, the demand for reliable and effective PCR technologies is on the rise. Multiplex real-time PCR enables researchers to amplify and quantify multiple genetic sequences simultaneously, providing a more detailed genetic analysis. This is particularly useful in genetic research, oncology, and the study of infectious diseases, where understanding the interactions between multiple genes and pathogens can lead to breakthroughs in treatment and prevention.

Real-Time PCR Assays have revolutionized the field of molecular diagnostics by providing a rapid and accurate method for detecting and quantifying nucleic acids. These assays are essential in various applications, including clinical diagnostics, where they enable the detection of pathogens, genetic mutations, and other biomarkers with high sensitivity and specificity. The ability to perform real-time monitoring of the amplification process allows for precise quantification of target sequences, making Real-Time PCR Assays a valuable tool in research and clinical settings. The integration of these assays with advanced data analysis software further enhances their utility, providing comprehensive insights into genetic and infectious disease profiles.

Moreover, the rising occurrences of chronic diseases such as cancer and genetic disorders are driving the adoption of multiplex real-time PCR in clinical diagnostics. These technologies offer high sensitivity and specificity, crucial for detecting low-abundance genetic materials in complex biological samples. As healthcare providers and patients increasingly demand personalized medicine, the ability to accurately detect and quantify multiple genetic markers in a single assay becomes invaluable, facilitating tailored treatment plans that improve patient outcomes.

In terms of regional outlook, North America holds the dominant position in the multiplex real-time PCR market, attributed to the presence of advanced healthcare infrastructure, high research funding, and the significant demand for diagnostic testing. Europe follows closely, driven by increasing healthcare expenditure and robust research activities. The Asia Pacific region is expected to witness the fastest growth over the forecast period, fueled by the rapid development of healthcare infrastructure, rising awareness about advanced diagnostic technologies, and increasing incidences of infectious diseases. Latin America and the Middle East & Africa are also anticipated to exhibit considerable growth, albeit at a slower pace, due to improving healthcare facilities and rising investments in healthcare and research sectors.

Product Type Analysis

The multiplex real-time PCR market is segmented by product type into instruments, reagents and consumables, and software and services. Instruments constitute a significant portion of the market, driven by the increasing need for advanced diagnostic tools in clinical and research settings. These instruments are essential for conducting PCR assays with high accuracy and efficiency, making them indispensable in modern laboratories. Technological advancements have led to the development of more sophisticated instruments that offer higher throughput, automation, and integrati

The global real-time fluorescence quantitative PCR (qPCR) instrument market is experiencing robust growth, driven by increasing demand for rapid and accurate diagnostic testing, particularly in the pharmaceutical and research sectors. The market's expansion is fueled by several key factors, including the rising prevalence of infectious diseases, the growing adoption of personalized medicine, and the increasing need for efficient drug discovery and development. Technological advancements leading to improved sensitivity, speed, and automation of qPCR instruments further contribute to market growth. The pharmaceutical industry is a significant driver, leveraging qPCR for drug efficacy testing, while research institutions utilize the technology for gene expression analysis and other critical research applications. Segmentation by channel type (single, dual, multi-channel) reflects varying needs for throughput and complexity of experiments. While the market is geographically diverse, North America and Europe currently hold a substantial market share due to well-established healthcare infrastructure and research capabilities. However, Asia-Pacific is anticipated to witness significant growth in the coming years due to increasing investments in healthcare infrastructure and rising disposable incomes. Competition within the market is intense, with established players like Thermo Fisher Scientific and Bio-Rad Laboratories facing challenges from emerging regional companies, leading to innovation and price competitiveness. Market restraints include the high cost of instruments, the need for skilled personnel to operate them, and regulatory hurdles associated with new diagnostic applications. Nevertheless, the overall market outlook remains positive, projecting continued growth over the forecast period. The forecast period (2025-2033) anticipates a sustained rise in qPCR instrument adoption, propelled by the continued expansion of the pharmaceutical and research sectors. The ongoing development of advanced features, such as multiplexing capabilities and improved data analysis software, will likely drive demand. Furthermore, the increasing prevalence of chronic diseases and the growing need for early and accurate diagnostics will further fuel market growth. The rising demand for point-of-care diagnostics and the development of portable qPCR systems are also expected to contribute to market expansion. While regulatory landscape variations across regions may present certain challenges, the overall trend towards increased investment in healthcare infrastructure, especially in emerging economies, should offset these concerns. This growth trajectory suggests an attractive investment opportunity for stakeholders involved in the manufacturing, distribution, and development of real-time fluorescence quantitative PCR instruments.

The Digital PCR (dPCR) and Real-Time PCR (qPCR) market has emerged as a pivotal segment within the biotechnology and healthcare sectors, underpinning advances in genetic research, infectious disease diagnostics, and personalized medicine. Both dPCR and qPCR are essential techniques for amplifying and quantifying nuc

The global digital PCR (dPCR), real-time PCR (qPCR), and quantitative PCR (qPCR) market is experiencing robust growth, driven by increasing applications in life sciences research, diagnostics, and personalized medicine. The market, estimated at $2.5 billion in 2025, is projected to achieve a Compound Annual Growth Rate (CAGR) of 10% from 2025 to 2033, reaching approximately $6 billion by 2033. Key drivers include the rising prevalence of infectious diseases demanding rapid and sensitive diagnostic tools, the growing adoption of personalized medicine necessitating precise quantification of genetic material, and continuous technological advancements leading to higher throughput, improved accuracy, and reduced assay costs. Furthermore, the increasing demand for automation and high-throughput screening in research and clinical laboratories fuels market expansion. Segmentation reveals strong growth in applications such as infectious disease diagnostics, oncology research, and pharmacogenomics. Within the types segment, dPCR is exhibiting significant growth due to its ability to offer absolute quantification without reliance on standard curves, making it ideal for applications requiring high precision. Major players such as Thermo Fisher, Roche, QIAGEN, and Bio-Rad are dominating the market, through continuous innovation, strategic partnerships, and mergers and acquisitions. However, the emergence of smaller companies specializing in niche applications and innovative technologies presents both opportunities and challenges. While market growth is promising, certain restraints exist, including the high initial investment costs associated with dPCR systems, the complexity of data analysis, and regulatory hurdles for certain diagnostic applications. Despite these, the market is expected to continue its upward trajectory, propelled by increasing funding for research and development, particularly in emerging economies and increasing collaborations between academic institutions and industry players. The North American market currently holds the largest share, followed by Europe, with Asia-Pacific poised for significant growth in the coming years.

The database includes the raw data of the article “Comparison of two RNA Extraction Methods for the Molecular Detection of SARS-CoV-2 from nasopharyngeal swab samples”.

Aim of this work was to compare a two commercially available kit for viral RNA extraction from human swab samples that differ mainly for time consuming (9 min. vs 35 min.) in order to improve SARS-CoV-2 diagnostic workflow.

The database contains the data obtained by the following evaluations:

a) RNA analysis for the evaluation of quality and quantity by nanodrop instrument

b) Real Time PCR analysis of SARS-CoV-2 genes and internal control.

The two procedures evaluated gave similar analytical results in terms of extracted RNA analysis and Real Time PCR data for gene expression.

Real Time PCR (qPCR) Instruments Market Outlook

The global market size of Real Time PCR (qPCR) instruments was valued at approximately USD 4.5 billion in 2023 and is projected to reach around USD 7.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% over the forecast period. This robust growth can be attributed to the rising prevalence of infectious diseases, increasing research and development activities, and the technological advancements in the field of genetic analysis.

One of the primary growth drivers of the qPCR instruments market is the increasing prevalence of infectious diseases globally. The need for accurate and efficient diagnostic tools has surged, particularly in the wake of pandemics like COVID-19. Real Time PCR has proven to be a gold standard in molecular diagnostics due to its high sensitivity and specificity. Additionally, the growing incidence of chronic diseases such as cancer and genetic disorders has further bolstered the demand for qPCR instruments, as they play a crucial role in early disease detection and monitoring.

Another significant factor contributing to the market's growth is the continuous advancements in qPCR technology. Innovations such as digital PCR, high-throughput systems, and the integration of artificial intelligence in data analysis are enhancing the efficiency, accuracy, and user-friendliness of these instruments. These technological improvements are enabling researchers and clinicians to perform complex genetic analysis more efficiently, thereby expanding the scope of qPCR applications in various fields including clinical diagnostics, research, and forensics.

Moreover, the increasing investments in research and development by both public and private sectors are expected to drive the market further. Governments and private organizations are funding extensive research in genomics and molecular biology, which in turn, is creating a substantial demand for qPCR instruments. The rise in personalized medicine, which relies heavily on genetic analysis, is also contributing to the market's growth. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, a process that requires precise and rapid genetic information, a capability provided by qPCR technology.

Regionally, North America holds the largest share of the qPCR instruments market, driven by the presence of advanced healthcare infrastructure, significant research and development activities, and the high prevalence of chronic diseases. Europe follows closely, with substantial investments in healthcare and research. The Asia Pacific region is anticipated to exhibit the highest CAGR during the forecast period, attributed to the increasing healthcare expenditure, growing research activities, and the rising awareness about early disease diagnosis and personalized medicine in countries like China, Japan, and India.

Product Type Analysis

The Real Time PCR (qPCR) instruments market can be segmented by product type into instruments, reagents, software, and services. Each of these segments plays a crucial role in the overall functionality and application of qPCR technology in various fields.

The instruments segment is the backbone of the qPCR market, encompassing the actual devices used for the amplification and quantification of DNA and RNA sequences. These instruments have seen significant advancements over the years, including improvements in sensitivity, multiplexing capabilities, and user interface. The adoption of high-throughput qPCR instruments is particularly notable in large-scale research and clinical laboratories, where the capacity to analyze multiple samples simultaneously is a critical factor. The growing demand for rapid and accurate diagnostic tools in the wake of the COVID-19 pandemic has further propelled the instruments segment.

Reagents form another essential component of the qPCR market, including enzymes, master mixes, and probes required for the amplification process. The quality and efficiency of reagents are pivotal for the accuracy and reliability of qPCR results. The market for reagents is driven by the continuous development of novel and more efficient reagents that can enhance the performance of qPCR assays. Additionally, the recurrent nature of reagent purchases offers a steady revenue stream for manufacturers, making this segment highly lucrative.

Software solutions in the qPCR market are designed to facilitate data analysis, interpretation, and management. These software tools are increas

The global real-time PCR instrument market is experiencing robust growth, driven by the increasing prevalence of infectious diseases, expanding applications in research and diagnostics, and advancements in technology leading to higher sensitivity and throughput. The market's size in 2025 is estimated at $2.5 billion, considering the typical market size for similar technologies and a moderate CAGR of 8%. This growth is projected to continue, with a forecast period of 2025-2033 exhibiting a compound annual growth rate (CAGR) that is expected to remain above 7%, reaching an estimated value exceeding $4 billion by 2033. Key drivers include the rising demand for rapid and accurate diagnostic testing, particularly in infectious disease management and personalized medicine. The integration of real-time PCR into high-throughput platforms, coupled with the development of more user-friendly and cost-effective instruments, fuels market expansion. Furthermore, increasing government funding for research and development in life sciences, particularly in areas such as oncology and infectious disease research, significantly contributes to the market's growth trajectory. However, certain restraints exist, primarily associated with the high cost of instruments and reagents, as well as the need for skilled personnel for operation and data analysis. Regulatory hurdles in obtaining approvals for new instruments and assays also impact market growth. Despite these challenges, the market is segmented into several key areas: instrument type (e.g., 96-well, 384-well), application (e.g., infectious disease diagnostics, gene expression analysis, pharmacogenomics), and end-user (e.g., hospitals, research institutions, pharmaceutical companies). Major players like Thermo Fisher Scientific, Roche, Bio-Rad, Qiagen, Agilent, Bioer, Analytik Jena, Techne, and Biosynex are actively competing through technological innovation, strategic partnerships, and geographical expansion. The North American market currently holds a significant share, but regions like Asia-Pacific are expected to exhibit faster growth due to rising healthcare spending and increasing disease prevalence.

Adult and neonatal human cardiovacular progenitor cell clonal populations were flown aboard the ISS for 12 days prior to fixation in RNAprotect. Gene expression analysis was performed against clone-, patient-, and passage-matched ground control samples. qPCR gene expression profiling. Human CPCs from three neonates and three adults were individually cultured on the ground or aboard the ISS.

Worldwide demand for real-time PCR qPCR systems is estimated at a market value of US$ 4.19 billion in 2024. The global real-time PCR qPCR market is forecasted to expand at 8.3% CAGR and reach US$ 9.31 billion by the end of 2034.

Report Attribute	Detail
Real-Time PCR qPCR Market Size (2024E)	US$ 4.19 Billion
Forecasted Market Value (2034F)	US$ 9.31 Billion
Global Market Growth Rate (2024 to 2034)	8.3% CAGR
North America Market Share (2024E)	38%
East Asia Market Value (2024E)	US$ 637 Million
Sales of Reagents and Assays (2034F)	US$ 4.17 Billion
Revenue from Use in Research (2034F)	US$ 5.33 Billion
Revenue from Use in Academic and Research Institutes (2034F)	US$ 2.36 Billion
Key Companies Profiled	Analytik Jena AG; Lumex Instruments; Agilent Technologies Inc.; Takara Bio Inc.; Bio-Rad Laboratories Inc.; Medtronic Plc; Abbott; Thermo Fisher Scientific, Inc.; Fluidigm Corporation; Cyberomic, Inc.; GE Healthcare.

Country-wise Insights

Attribute	United States
Market Value (2024E)	US$ 1.35 Billion
Growth Rate (2024 to 2034)	8.2% CAGR
Projected Value (2034F)	US$ 2.96 Billion

Attribute	Japan
Market Value (2024E)	US$ 228 Million
Growth Rate (2024 to 2034)	8.2% CAGR
Projected Value (2034F)	US$ 504 Million

Category-wise Insights

Attribute	Reagents and Assays
Segment Value (2024E)	US$ 1.8 Billion
Growth Rate (2024 to 2034)	8.7% CAGR
Projected Value (2034F)	US$ 4.17 Billion

Attribute	Academic & Research Institutes
Segment Value (2024E)	US$ 1.05 Billion
Growth Rate (2024 to 2034)	8.4% CAGR
Projected Value (2034F)	US$ 2.36 Billion

Some U.S bioethanol plants use a blend of maize and sorghum grains as feedstocks depending on availability and price. Knowledge of the grain composition of milled feedstock is beneficial for maximizing process efficiency and for potential future regulatory requirements. To analyze feedstock composition, we developed a duplex real-time PCR assay based on TaqMan™ probes for the simultaneous analysis of flour blends. For sorghum, the method amplified a sequence within the F-Box _domain-containing protein and for maize, the method amplified a sequence of the high mobility group a (HMGa) proteins. To acquire fluorescent signals simultaneously, FAM and TAMRA fluorescent probes were used to label the sorghum- and maize- specific probes, respectively. Results showed that the primers and probes were highly specific either for maize or sorghum. The real-time duplex PCR assay was validated on simulated flour binary mixtures and high in the precision and accuracy for the sorghum PCR system. Results with the established method showed specificity and sensitivity in quantifying sorghum composition in bioethanol feedstock mixtures. Resources in this dataset: Resource title: Primer sets used File name: Table 1 1.jpg Resource title: Experimental setup File name: experiemntal set ups Real time PCR project Sorgh-Maize.xlsx Resource title: Multiplex data HMGa and FBox File name: 2022-01-24 multiplex FBox - HMGa 60 C 200nM.xls Resource description: Data and analysis of sorhum maize and miusxtures using HMGa and FBox genes Resource title: multiplex FBox HMGa flour mixes 60 C File name: 2022-02-22 multiplex FBox HMGa flour mixes 60 C 11 points.xls Resource description: PCR multiplex data FBox HMGa flour mixes 60 C Resource title: Standard curves for zein DNA HMGa gene File name: 2022-01-11 Hmga - Zein X07535 standard curves.xls Resource description: Standard curves for zein DNA HMGa gene detection

HF183/BacR287 qPCR standard control material and water sample measurements used to compare Bayesian and Traditional Fecal Score models. This dataset is associated with the following publication: Sivaganesan, M., J. Willis, A. Diedrich, and O. Shanks. A fecal score approximation model for analysis of real-time quantitative PCR fecal source identification measurements. WATER RESEARCH. Elsevier Science Ltd, New York, NY, USA, 255: 121482, (2024).

The real-time polymerase chain reaction (RT-PCR) technology market is experiencing robust growth, driven by the increasing prevalence of infectious diseases, rising demand for rapid diagnostics, and advancements in molecular diagnostics. The market's expansion is fueled by the crucial role RT-PCR plays in detecting and monitoring various pathogens, including viruses like influenza and COVID-19, bacteria, and parasites. The development of more sensitive and specific assays, coupled with the integration of automation and point-of-care testing, further enhances the technology's appeal across diverse healthcare settings. Hospital and clinic applications currently dominate the market, although the "others" segment (e.g., research labs, veterinary clinics) shows significant growth potential. The segment featuring RT-PCR with real-time fluorescence detection holds a larger market share due to its superior accuracy and speed compared to methods without real-time detection. Key players, including Thermo Fisher, BGI, and others, are investing heavily in research and development to improve assay performance, expand applications, and capture larger market segments. Geographic regions such as North America and Europe currently lead in market adoption due to established healthcare infrastructures and higher diagnostic testing rates. However, Asia Pacific is witnessing significant growth, driven by increasing healthcare expenditure and rising awareness of infectious diseases in rapidly developing economies. Despite the growth, market restraints include the high cost of instruments and reagents, stringent regulatory approvals, and the need for skilled personnel to operate sophisticated equipment. The forecast period (2025-2033) anticipates continued expansion of the RT-PCR market, fueled by ongoing advancements in technology and the increasing need for faster and more accurate diagnostic solutions. The market is expected to witness the emergence of new applications, such as personalized medicine and pharmacogenomics. Furthermore, integration with artificial intelligence and big data analytics will likely drive further sophistication in data analysis and diagnostic efficiency. Competition among existing players will remain intense, with mergers, acquisitions, and strategic partnerships shaping the market landscape. Emerging economies will play a critical role in shaping future growth, particularly as access to improved healthcare infrastructure expands. Strategies focusing on cost-effectiveness, user-friendliness, and portability of RT-PCR systems will likely gain traction.